NAC/AEGI	. Meeting	48: /	April	14-16.	2009
----------	-----------	-------	-------	--------	------

Chemical: MINUTES & CAS Reg. No.: Appendix A

Action: Proposed_____ Interim____ Other_____

Chemical Manager:					Staff Scientist:								
NAC Member	AEGL1	AEGL2	AEGL3	LOA	NAC Member	AEGL1	AEGL 2	AEGL3	LOA				
Henry Anderson					John Hinz								
Marc Baril					Jim Holler			-					
Lynn Beasley					Glenn Leach								
Alan Becker					Richard Niemeier								
Robert Benson			-		Susan Ripple								
Edward Bernas					George Rusch, Chair								
Iris Camacho					Daniel Sudakin								
Gail Chapman					Marcel vanRaaij			-					
George Cushmac					Calvin Willhite			· ·					
David Freshwater					George Woodall								
Ralph Gingell					Alan Woolf			-					
Roberta Grant						-		-					
Dieter Heinz				1					<u> </u>				
					TALLY	7							
		L	<u> </u>		PASS/ FAIL	1							

$PPM, (mg/m^3)$	10 M	lin	30 Mi	n	1 Hr		4 Hr		8 Hr	
AEGL 1	.,(_)	- ,(-) -	, , ()			••()_
AEGL 2	,()	,()	,()	,()	,()
AEGL 3	,()	,()	,()	,()	,()
LOA								I		
* = ≥10% LEL										
** = ≥ 50% LEL	1									
*** = ≥100% LEL										

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

& UHANIMOUS

NR= Not Recommended due to_____

AEGL 1	Motion by: <u>HEINZ</u>	Second by: <u>(</u>	HAPMAN
AEGL 2	Motion by:	Second by:	
AEGL 3	Motion by:	Second by:	
LOA	Motion by:	Second by:	
Approved	by Chair: h. h. DFO:_	Pauls Mi	Date: <u>4/14/09</u>

1 2	National Advisory Committee (NAC) for Acute Exposure Guideline Levels (AEGLs) for Hazardous Substances
3 4	December 3-5, 2008
5 6	Final Meeting-47 Highlights
7	8 8 8
8	Holiday Inn
9	1355 North Harbor Drive
10 11	San Diego, CA
12	
13	
14	INTRODUCTION
15	
16	George Rusch opened the meeting which was followed by introductions of all participants.
17 18	George Rusch opened the meeting which was followed by introductions of all participants.
19	The draft NAC/AEGL-46 meeting highlights were reviewed. A motion to accept the minutes as
20	written was made by Dieter Heinz (second by Henry Anderson) and passed unanimously
21	(Appendix A). The Final NAC/AEGL-46 meeting highlights are included as Appendix B.
22	The 's The II and the state of the NL (1, 1, 1, 1, 1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,
23 24	Ernie Falke provided a status update on the National Academy of Science (NAS) publications. Volume 6 is published and additional volumes are under way. The Technical Support Document
24 25	(TSD) and AEGL values for carbon monoxide can be finalized.
26	
27	The highlights of the NAC/AEGL-47 meeting are summarized below along with the Meeting
28	Agenda (Attachment 1) and the Attendee List (Attachment 2). The subject categories of the
29	highlights do not necessarily follow the order listed in the NAC/AEGL-47 Agenda.
30 31	
32	
33	STANDING OPERATING PROCEDURES (SOP) REVISIONS
34	
35	Ernie Falke briefly described the status of the SOP addendum. The committee asked for a list of
36	SOP issues at the next AEGL meeting. The Physiologically-Based Pharmacokinetic Modeling
37	(PBPK) white paper will be posted on the AEGL website. In addition, TSD postings are under
38	way. Only clean TSDs (not markup documents) will be posted on the AEGL website. The
39 40	AEGL website is being revised and a new format will be posted in December. The committee requested to be informed when the new format is available. Therefore, an email will be sent to
41	the committee members when the new voltat is available.
42	
43	
44	
45 46	
40 47	

1	LOA DISCUSSION
2	
3	The LOA paper is scheduled to be published as an RIVM publication in December and should be
4	available on the website in 2009. Also, the paper will be sent to Don Gardner for publication in
5	Inhalation Toxicology.
6 7	
8	CHEMICAL LIST
8 9	
10	There was considerable discussion regarding the source and criteria for chemicals to be
11	considered for AEGL development. Possible criteria for adding a chemical to the priority list
12	included sufficient vapor pressure, production and use data, and toxicity sufficient for concern.
13	The NAC felt that it was important to know who was nominating chemicals for AEGL
14	development and for what reasons. The committee also discussed putting together a guidance
15	document listing chemical selection criteria and the possibility of publishing a list of tabled
16	chemicals in an FR notice.
17	
18	CHLOROSILANES GROUPING
19	
20	Staff Scientist: Cheryl Bast, ORNL
21	Chemical Manager: Ernest Falke, U.S. EPA
22	
23	Background information was provided by Cheryl Bast (Attachment 3). The NAC has developed
24	AEGL values for 24 chlorosilanes. Twenty-one of these were developed at NAC-43 and NAC-
25	44, are based on analogy to hydrogen chloride, and are presented in one TSD. The other three
26	(dimethyldichloro-, trimethylchloro-, and methyltrichloro-silanes) were derived prior to NAC-
27	43, are each presented in separate TSDs and values are based on chemical-specific data where
28 29	available. The proposal is to incorporate all chlorosilanes into one TSD and use the HCl analogy
29 30	approach for consistency. George Rusch recommended adding the derivation of the individual TSDs as an appendix in the new TSD. The revised TSD will contain all 24 chlorosilanes and
31	derivation will be based on analogy to hydrogen chloride. The revised document should contain
32	a discussion on the impact of bulky groups in the hydrolysis of the chlorosilane. Also, the
33	revised document will include a table of the hydrolysis rates for the various chlorosilanes and
34	will note those that do not have data. A motion (Marcel Van Raaij /John Hinz) was made to
35	adopt the proposed AEGL values for the 3 chlorosilanes under consideration. The motion was
36	approved unanimously (Appendix C: 22 yes; 0 no; 0 abstain).
37	

Compound	Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference
Trimethylchlorosilane	AEGL-1	1.8 ppm	Hydrogen chloride (HCl) AEGL-1 values adopted as AEGL-1 values (NRC, 2004)				
	AEGL-2	100 ppm	43 ppm	22 ppm	11 ppm	11 ppm	Hydrogen chloride (HCl) AEGL-2 values adopted as AEGL-2 values (NRC, 2004)
	AEGL-3	620 ppm	210 ppm	100 ppm	26 ppm	26 ppm	Hydrogen chloride (HCl) AEGL-3 values adopted as AEGL-3 values (NRC, 2004)
	AEGL-1	0.90 ppm	HCl AEGL-1 values divided by a molar adjustment factor of 2 adopted as AEGL-1 values (NRC, 2004)				
Dimethyldichlorosilane	AEGL-2	50 ppm	22 ppm	11 ppm	5.5 pm	5.5 ppm	HCl AEGL-2 values divided by a molar adjustment factor of 2 adopted as AEGL-2 values (NRC, 2004)
	AEGL-3	310 ppm	110 ppm	50 ppm	13 ppm	13 ppm	HCl AEGL-3 values divided by a molar adjustment factor of 2 adopted as AEGL-3 values (NRC, 2004)
Methyltrichlorosilane	AEGL-1	0.60 ppm	HCl AEGL-1 values divided by a molar adjustment factor of 3 adopted as AEGL-1 values (NRC, 2004)				
	AEGL-2	33 ppm	14 ppm	7.3 ppm	3.7 ppm	3.7 ppm	HCl AEGL-2 values divided by a molar adjustment factor of 3 adopted as AEGL-2 values (NRC, 2004)
	AEGL-3	210 ppm	70 ppm	33 ppm	8.7 ppm	8.7 ppm	HCl AEGL-3 values divided by a molar adjustment factor of 3 adopted as AEGL-3 values (NRC, 2004)

2

3

4

FEDERAL REGISTER 11- ACRYLONITRILE

5

6 Acrylonitrile (CAS No. 107-13-1) was the only chemical for which comments were received.

7 Comments received from the AN Group on the FR submission for acrylonitrile were summarized

by Robert Young (ORNL) (Attachment 4). The AN Group commended the NAC/AEGL for a
 thorough and thoughtful TSD. The AN Group suggested minor adjustment to uncertainty factor

application resulting from PB-PK model results. Because the numerical adjustments were

somewhat unorthodox relative to AEGL SOP guidelines and because the PB-PK model results

12 were already incorporated into the development of the proposed AEGL values, it was decided

13 unanimously to retain the original NAC/AEGL assessment. Additional reports regarding

developmental/ reproductive studies on AN will be incorporated into the TSD as suggested by

15 the AN Group. Consistent with AN suggestions, the cancer risk section will reflect current

assessments of epidemiology reports and IARC decisions regarding no causal relationship for

cancer risk from AN exposure. Bob Benson agreed to submit a write-up to this effect. George
 Woodall will offer the revision to the IRIS staff for comment.

- 18 wooda 19
- 20

21 ORGANOPHOSPHATE (OP) UNCERTAINTY FACTOR ISSUES

22

23 John Hinz and George Woodall led a discussion session on OP uncertainty issues in conjunction

with a presentation (via teleconference) with Virginia Moser (U.S. EPA ORD) (Attachment 5).

25 General information on the various targets of OPs and the metabolism of OPs were provided

with respect to impact on interspecies and intraspecies uncertainty factors. Additionally,

summary information for the specific OPs scheduled for discussion at the meeting were also

- 28 provided. Although uncertainty factor selection and justification is always a chemical-specific
- 29 issue, inhalation data on OPs are often very limited. Use of default uncertainty factors
- 30 (currently 3 for interspecies and 10 for intraspecies) selection/justification will require careful
- 31 consideration on a chemical-by-chemical basis.

1	
2	
3	CHEMICAL REVISITS/STATUS UPDATES
4	
5	
6	No Data Chemicals
7	
8	Cheryl Bast (ORNL) provided a status update for aluminum chloride, antimony pentafluoride,
9	phosphorus pentafluoride, and phosphorus pentasulfide. These chemicals have no data and will
10	be placed in holding status.
11	The committee commented on the 12 chemicals that did not have AEGL values (as described in
12	the NAC-46 highlights). The following recommendations were made:
13	a. Identify criteria for chemical selection and publish it in the addendum of the SOP. This
14	suggestion was made by Calvin Willhite.
15	b. Publication of tabled chemicals in a FR notice requesting additional data for AEGL
16	development.
17	c. Refer chemicals to groups that have a structure-activity background.
18	
19	
20	
21	Methyl Iodide (CAS No. 74-88-4)
22	
23	Staff Scientist: Sylvia Talmage, ORNL
24	Chemical Manager: Alan Becker, Missouri St. Univ.
25	A status update was provided by Sylvia Talmage. Industry is still working on the PBPK
26 27	modeling results for methyl iodide.
28	modeling results for methyr founde.
29	
30	Allyl Alcohol (CAS No. 107-18-6)
31	
32	Staff Scientist: Claudia Troxel, ORNL
33	Chemical Manager: Bob Benson, U.S. EPA
34	
35	Bob Benson, the chemical manger, made brief introductory remarks on this chemical. The
36	chemical has been considered by the NAC and reviewed by the COT multiple times. At the
37	December, 2006, NAC meeting, Dr. Marcy Banton, a representative of Lyondell, the sole US
38	manufacturer of allyl alcohol, offered to ask her company to sponsor an additional study to help
39	resolve the issues that led to the lack of agreement by the COT of the AEGL values derived by
40	the NAC. Dr. Banton was successful in her effort. The new study was completed earlier this
41	year. Dr. Jeff Fowles, the present representative of Lyondell Basell, presented a brief summary
42	of the results of this new study (Attachment 6). Claudia Troxel then began a discussion of the
43	data available on the chemical and the reasons for the previous lack of agreement between the
44	NAC and COT on the AEGL values (Attachment 7). New AEGL-3 values were derived based on the LC from all the ret studies showing lethelity using the ten Borge regression program
45 46	on the LC_{01} from all the rat studies showing lethality using the ten Berge regression program with $n = 0.95$ and a total uncertainty factor of 10 (3 each for interspecies and intraspecies
46 47	with $n = 0.95$ and a total uncertainty factor of 10 (3 each for interspecies and intraspecies extrapolation). The values are 260 ppm, 82 ppm, 40 ppm, 9.3 ppm, and 4.5 ppm for 10 minutes
47 48	to 8 hours, respectively. AEGL-2 values were calculated by deriving the AEGL-3 values by 3
40 49	because the NOEL for severe, irreversible nasal lesions was virtually identical to the exposure-
1)	because the restance for severe, merersione husar resions was virtually recitical to the exposure
	4

- response relationship for lethality. The AEGL-2 values are 87 ppm, 27 ppm, 13 ppm, 3.1 ppm, 1
- and 1.5 ppm for 10 minutes to 8 hours, respectively. John Hinz moved that the AEGL-3 and 2
- AEGL-2 values be accepted. Mark Baril seconded the motion. The motion passed (Appendix 3
- D: 19 ves: 0 no; 1 abstain). Possibilities for AEGL-1 values included the human data for eve 4 irritation from a 5 minute exposure with values of 2.1 for 10, 30, and 60 minutes, and Not
- 5 Recommend for longer durations; the new laboratory animal study in rats showing nasal 6
- inflammation 14 days after exposure (9.3 ppm, 6.4 ppm, 5.1 ppm, 2.2 ppm, and 1.0 ppm for 10 7
- minutes to 8 hours, respectively); the new laboratory animal study in rats showing nasal 8
- degeneration 14 days after exposure (21 ppm, 21 ppm, 6.8 ppm, 0.68 ppm, and 0.21 ppm for 10 9
- minutes to 8 hours, respectively); and the new laboratory animal study in rats showing a 10
- lessening of the startle response during exposure (14 ppm, 5.3 ppm, 3.2 ppm, 0.9 ppm, and 0.5 11
- ppm for 10 minutes to 8 hours, respectively. Bob Benson made the motion to accept the values 12
- based on nasal inflammation. George Woodall seconded the motion. The motion passed 13
- (Appendix D: 20 yes; 0 no; 0 abstain). 14
- 15
- COD 16
- 17 18

16	These discussions identified an SOP issue regarding analysis of data using the ten Berge program
17	and whether to report only the 1% response or lower limit of the 5% response.

Summary of AEGL Values for Allyl Alcohol									
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)			
AEGL-1 (Nondisabling)	9.3 ppm	6.4 ppm	5.1 ppm	2.2 ppm	1.0 ppm	Nasal inflammation in rats (Kirkpatrick, 2008)			
AEGL-2 (Disabling)	87 ppm	27 ppm	13 ppm	3.1 ppm	1.5 ppm	Severe, irreversible lesions in rats (Kirkpatrick, 2008)			
AEGL-3 (Lethal)	260 ppm	82 ppm	40 ppm	9.3 ppm	4.5 ppm	LC ₀₁ (Combined rat data)			

Tear Gas (CAS No. 2698-41-1)

19

- 20
- 21
- 22
- 23
- 24 25

Staff Scientist: Cheryl Bast, ORNL

26 Chemical Manager: Glenn Leach, U.S. Army CHPPM 27

28

29 Cheryl Bast presented a summary of the available data and an overview of the development of proposed AEGL values for tear gas (Attachment 8). Proposed AEGL-1 values were based on 30 human exposure to 1.5 mg/m³ for 90 minutes (Punte et al., 1963), an exposure tolerated by all 4 31 subjects but resulting in ocular and nasal irritation and headache. One subject developed nasal 32 irritation within 2 minutes, three subjects developed headache (at 45, 50, and 83 minutes), and all 33 34 four experienced ocular irritation (at 20, 24, 70, and 75 minutes). The intraspecies uncertainty factor was limited to 3 because contact irritation is a portal-of-entry effect and is not expected to 35 vary widely among individuals and was supported by the fact that responses of volunteers with 36 jaundice, hepatitis, or peptic ulcer or those that were 50-60 years old were similar to those of 37 "normal" volunteers when exposed to a highly irritating concentration of CS for short durations 38 39 (Punte et al., 1963; Gutentag et al., 1960). The interspecies uncertainty factor was 1 was due to the use human data. A modifying factor of 10 was applied to reduce the point-of-departure from 40

REVIEW of PRIORITY CHEMICALS

a LOEL to a NOAEL for effects defined by AEGL-1. Time scaling was not applied in the 1 development of the AEGL-1 values, because the critical effect (irritation) is a function of direct 2 contact with the tear gas and is not likely to increase with duration of exposure at this level of 3 severity (NRC, 2001). The AEGL-2 values were based on the same point-of departure as the 4 AEGL-1 values. Uncertainty factor application was the same as for the AEGL-1 derivation 5 described above. However, no modifying factor was applied in the derivation of AEGL-2 6 values, because the observed effects meet the definition of AEGL-2. The AEGL-2 values were 7 held constant across time. The AEGL-3 values were based on the threshold for lethality at each 8 AEGL-3 exposure duration calculated using the probit-analysis based dose-response program of 9 ten Berge (2006). The assessment used rat lethality data (McNamara et al., 1969; Ballantyne and 10 Calloway, 1972; Ballantyne and Swantson, 1978) and the LC_{01} as the benchmark. The analysis showed a time-scaling value of 0.704 ($C^{0.704}$ x t = k). The 4-hour AEGL-3 value was adopted as 11 12 the 8-hour AEGL-3 value because time scaling yielded an 8-hour value inconsistent with the 13 AEGL-2 values that were derived from a rather robust human data set. Inter- and intraspecies 14 uncertainty factors of 3 each were applied (total 10) and were considered sufficient because 15 clinical signs are likely caused by a direct chemical effect on the tissues. This type of portal-of-16 entry effect is not likely to vary greatly between species or among individuals. The interspecies 17 UF of 3 is supported by calculated LCt₅₀ values of 88,480 mg min/m³ for rats; 67,200 mg min/m³ 18 for guinea pigs; 54,090 mg min/m³ for rabbits; and 50,010 mg min/m³ for mice (Ballantyne and 19 Swantson, 1978), values all well within a factor of two. The intraspecies UF of 3 is supported by 20 21 the fact that responses of volunteers with jaundice, hepatitis, or peptic ulcer or those that were 50-60 years old were similar to those of "normal" volunteers when exposed to highly irritating 22 23 concentration of CS for short durations (Punte et al., 1963; Gutentag et al., 1960).

24

25 A motion by John Hinz (Dieter Heinz second) to accept the values as proposed including AEGL-

- 1 values of 0.05 mg/m³ for all durations passed unanimously (Appendix E: 21 yes; 0 no; 0
- abstain). The AEGL-2 motion also passed (Appendix E: 21 yes; 0 no; 0 abstain), as did the
- AEGL-3 (Appendix E: 19 yes; 1 no; 1 abstain).
- 29

	Summary of AEGL Values for Tear Gas										
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)					
AEGL-1 (Nondisabling)	0.050 mg/m ³	0.050 mg/m ³	0.050 mg/m ³	0.050 mg/m ³	0.050 mg/m ³	Ocular/nasal irritation and headache in humans (Punte et al., 1963)					
AEGL-2 (Disabling)	0.50 mg/m ³	0.50 mg/m ³	0.50 mg/m ³	0.50 mg/m ³	0.50 mg/m ³	Ocular/nasal irritation and headache in humans (Punte et al., 1963)					
AEGL-3 (Lethal)	140 mg/m ³	29 mg/m ³	11 mg/m ³	1.5 mg/m ³	1.5 mg/m ³	Threshold for lethality (LC_{01}) in rats [McNamara et al.(1969); Ballantyne and Calloway (1972); and Ballantyne and Swantson (1978)]					

31

32

1											
2											
3				Ricin (O	CAS No. 9	009-86-3)				
4				,							
5	Staff Scientist: Robert Young, ORNL										
6	Chemical Manager: Jim Holler, ATSDR										
7		C									
8	Robert Young	g summa:	rized the d	ata for rici	in noting tl	nat inhala	tion data are especially limited and				
9	that there are	critical is	ssues regai	rding varia	ble potenc	y of such	a toxin (Attachment 9). Data are				
10	unavailable w	ith whic	h to derive	AEGL-1	values and	l, therefor	e, they are not recommended				
11	(motion by jo	hn Hinz,	second by	/ Jim Holle	er; Append	lix F: 22 y	yes, 0 no, 0 abstain). AEGL-2				
12	values were in	nitially d	erived bas	ed upon da	ata in rats s	showing c	changes in pulmonary function				
13							broach was tenuous. Specifically,				
14	rats exposed t	o a Ct of	16.7 mg•	min/m³ (≈l	LC_{25} ; cons	idered su	blethal by the investigators)				
15	showed a mile	d inflamı	natory res	ponse of ii	nsufficient	severity	to cause fluid accumulation in the				
16							ne assessment was conducted at 30				
17	hours post exp	posure w	hich the ir	nvestigator	s consider	ed an esti	mated time for peak injury.				
18							the gas exchange process in the				
1 9							red to be somewhat lower than that				
20			•		•	•	nt) and the exposure was noted as				
21	an LC ₂₅ . It wa	as the co	nsensus of	f the NAC	-AEGL tha	at this wa	s a tenuous approach and that no				
22	AEGL-2 valu	es be der	rived (mot	ion by Joh	n Hinz, see	cond by J	im Holler; Appendix F: 22 yes, 0				
23							lity data reported by Griffiths et al.				
24							k Dose software (U.S. EPA, 2008)				
25							Software of ten Berge (2006) was				
26							0.0015 mg/m^3 , respectively, for				
27							ime frames based upon an				
28							centration vs. ln minutes) of 0.95.				
29							in the potency of the ricin				
30							and intraspecies factors of 3 each				
31							animal studies were very short				
32	`` /				•		or AEGL-3 analysis ranged from 6				
33	to 12 minutes.	. Due to	uncertaint	ties in extr	apolating f	from these	e very short exposure durations, 4-				
34	hour and 8-ho	ur AEG	L-3 values	were not	recommen	ded. Foll	owing discussions focusing on the				
35							3, 0.010, and 0.0048 mg/m ³ for the				
36							ix F: 15 yes; 3 no; 1 abstain)				
37							Concern was expressed regarding				
38	•	1-hour	values bas	ed upon da	ta limited	to exposi	ure duration of only several				
39	minutes.										
40											
					alues for ric						
	Classification	<u>10-min</u>	<u>30-min</u>	<u>1-h</u>	<u>4-h</u>	<u>8-h</u>	Endpoint (Reference)				
	AEGL-1	NR	NR	NR	NR	NR	Not recommended; insufficient data				
	(Nondisabling)										

AEGL-1	NR	NR	NR	NR	NR	Not recommended; insufficient data
(Nondisabling)						
AEGL-2	NR	NR	NR	NR	NR	Not recommended; insufficient data
(Disabling)						
AEGL-3	0.033	0.010	0.0048	NR	NR	estimated lethality threshold (LC ₀₁) in
(Lethality)				ļ		rats (Griffiths et al., 1995a); values
			}			incorporate a 2.7-fold reduction for
						potency variability; UF=10 (3x3);
						n=0.95

1	
2	
3	
4	
5	
6	Dichlorvos (CAS No. 62-73-7)
7	
8	Staff Scientist: Jennifer Rayner, ORNL
9	Chemical Manager: John Hinz, AFIOH/RSRE
10	
11	Jennifer Rayner provided a review of the available data and draft AEGL values (Attachment
12	10). The draft AEGL-1 values were based on clinical exposure data showing that humans
13	exposed for 2-7 hours to ~0.11 ppm (1 mg/m ³) dichlorvos experienced only inhibition of plasma
14	cholinesterase activity (Hunter 1970a). The POD was $0.11 \text{ ppm} (1 \text{ mg/m}^3)$ and supported by an
15	occupational exposure data where workers exposed to an average concentration of 0.078 ppm
16	(0.7 mg/m^3) dichlorvos for 8 months experienced inhibition of plasma and erythrocyte

cholinesterase activity but experienced no adverse health effects during or 4 months following 17 exposure (Menz et al., 1974). The interspecies uncertainty factor for AEGL-1 was 1 because 18 human data were used, and the intraspecies uncertainty factor was 1 based on oral and inhalation 19 20 human data showing no sex-, age-, compromised health status-related differences in response to dichlorvos exposure. Following discussions, the data from Hunter (1970a) was selected as the 21 AEGL-1 values for all durations (motioned by Bob Benson; seconded by Dieter Heinz; vote 18 22 yes, 3 abstain, 0 no). The AEGL-2 values were based on a POD of 0.56 ppm (5 mg/m³) for rats 23 exposed for 45 min (Atis et al. 2002). At 1.1 and 1.7 ppm (10 and 15 mg/m³), the rats 24

25 experienced dyspnea, increased salivation, excessive urination and defecation, and alveolar degeneration but at 0.56 ppm there were no clinical signs of toxicity. This exposure, however, 26

27 did cause a shortening of epithelial cells in the trachea, loss of cilia from the ciliated cells of the

trachea as well as alveolar interstitial thickening, capillary congestion, and extravasated 28 29 erythrocytes. The POD was the highest experimental value without an AEGL-2 effect. This

POD was also based on a 2-yr study in rats (Blair et al. 1976). The rats were exposed to 30

dichlorvos 23 hr/d and exhibited no signs of organophosphate toxicity at 0.56 ppm (5 mg 31 dichlorvos (vapor)/m³) but male rats did have decreased body weight, consistently 20% or more 32

of control male rats from the 10th week of treatment until termination. The AEGL-2 values were 33

kept constant across all time points because the 2-yr study showed that prolonged exposure 34

would not result in an enhanced effect. The interspecies uncertainty factor for AEGL-1 was 1 35

36 because experimental data showed that humans are no more sensitive and possibly less sensitive than laboratory animals to dichlorvos, and the intraspecies uncertainty factor was 1 based on oral 37

and inhalation human data showing no sex-, age-, compromised health status-related differences 38

in response to dichlorvos exposure. Additionally, as AEGL values are set for vapor 39

40 concentrations, the Blair et al. (1976) vapor study shows that the POD is protective of the

population. The AEGL-2 values of 0.56 ppm (5 mg/m³) for all time points was unanimously 41 approved (motion by Bob Benson, second by Calvin Willhite, vote: 19 yes; 0 no; 2 abstain).

42 AEGL-3 values were not initially derived but, following committee deliberation, were based 43

upon the highest nonlethal exposure of (8 ppm $[72 \text{ mg/m}^3]$ for 16 hrs) in a study by Dean and 44

Thorpe (1972a). The interspecies uncertainty factor for AEGL-1 was 1 because experimental 45

data showed that humans are no more sensitive and possibly less sensitive than laboratory 46

animals to dichlorvos, and the intraspecies uncertainty factor was 1 based on oral and inhalation 47

human data showing no sex-, age-, compromised health status-related differences in response to 48

dichlorvos exposure. The AEGL-3 values of 8.0 ppm (72 mg/m³) for all time points was 49

1

			AEGL Val	ues for dich	lorvos (pp	m)
Classification	10-min	30-min	1 -h	4-h	8-h	Endpoint (Reference)
AEGL-1 (Nondisabling)	0.11	0.11	0.11	0.11	0.11	No effects in human volunteers exposed for 2-7 hours to 0.11 ppm (1 mg/m ³) (Hunter 1970a)
AEGL-2 (Disabling)	0.56	0.56	0.56	0.56	0.56	Highest experimental exposure without an AEGL-2 effect (0.56 ppm, 5 mg/m ³) (Atis et al. 2002)
AEGL-3 (Lethality)	8.0	8.0	8.0	8.0	8.0	Highest experimental exposure without a lethal effect (8.0 ppm, 72 mg/m ³) (Dean and Thorpe 1972a)

Dicrotophos (CAS No. 141-66-2)

6 7

8 Staff Scientist: Robert Young, ORNL 9 Chemical Manager: Bob Benson, U.S. EPA

10

22 23

24 25

Robert Young provided an overview of the inhalation data for this chemical (no human data and 11 only two studies in rats) with an emphasis on the marginal nature thereof (Attachment 11). Data 12 were not available for derivation of AEGL-1 values and AEGI-2 values. Data from one study 13 suggested a steep exposure-response relationship which was used to justify draft AEGL-2 values 14 as a 3-fold reduction of the AEGL-3 values. AEGL-3 values were initially based upon 1-hour 15 and 4-hour LC₅₀ value both of which were 90 mg/m³. After a brief discussion of the data and 16 their limitations, it was moved by Bob Benson to defer further discussion of this chemical to the 17 next meeting and reconsider dicrotophos in conjunction with monocrotophos. A motion to this 18 effect was made by Bob Benson, second by Calvin Willhite, and passed unanimously by a show 19 of hands. 20 21

Fenamiphos (CAS No. 22224-92-6)


- 26 Staff Scientist: Jennifer Rayner, ORNL
- 27 Chemical Manager: George Woodall, U.S. EPA
- Jennifer Rayner provided a brief overview the limited data for this chemical (Attachment 12).
 An attempt will be made to obtain a non-sanitized copy of a Bayer Corp. study (Thyssen, 1979)
 on the 4-hr exposure of rats which may of use in developing AEGL values. If obtained, these
 data may be used for 4-hr BMC analysis and ten Berge calculations. Further deliberations on
- this chemical were tabled (unanimous vote by show of hands).
- 34
- 35 36

- Malathion (CAS No. 121-75-5)
- 3738 Staff Scientist: Carol Wood, ORNL
- 39 Chemical Manager: John Hinz, AFIOH/RSRE
- 40

Carol Wood presented an overview of the draft TSD for malathion (Attachment 13). AEGL-1 1 and AEGL-2 were based upon data from a subchronic inhalation study in Sprague-Dawley rats 2 (US EPA 2000) exposed to malathion (96.4% a.i.) aerosols (in air) at concentrations of 0, 100, 3 450 or 2010 mg/m³, 6 hours/day, 5 days/week for 13 weeks. The 6-hour exposure to 450 mg/m³ 4 was chosen as the POD for derivation of AEGL-1 values. Because clinical signs at the point of 5 departure were sporadic and cholinesterase activity inhibition was not biologically significant 6 after the 13-week exposure, time scaling was not performed. The total uncertainty factor of 30 7 includes 10 for intraspecies extrapolation to account for the documented variability in sensitivity 8 among different age groups and genders, and the known genetic polymorphisms in A-esterases 9 and 3 for interspecies extrapolation to account for the differences in serum carboxylesterase 10 levels between humans and rata. The 2010 mg/m³ exposure for 6 hours was the POD for AEGL-11 2 values. Critical effects after 13-week exposure included microscopic lesions and significant 12 inhibition of brain cholinesterase activity. A total uncertainty factor of 30 was applied as for 13 AEGL-2 with time scaling using default values of n = 3 for extrapolating to the 30-minute, 1-14 hour, and 4-hour time points and n = 1 for the 8-hour time point (30-minute value was adopted as 15 the 10-minute AEGL-2 value as per AEGL SOP). A motion to accept the AEGL-1 and AEGL-2 16 values as presented was made by Bob Benson and second by Jim Holler. The motion passed 17 (Appendix H: 21 yes, 0 no, 0 abstain). AEGL-3 values for malathion were not recommended in 18 the draft TSD. Following discussion, the NAC/AEGL decided to base AEGL-3 values on a POD 19 of 6900 mg/m³ (5-hr exposure) which represented the highest exposure for any species. The 20 uncertainty factor application (total of 30) and time scaling (default) were as for AEGL-1 and 21 AEGL-2. AEGL-3 values (expressed as mg/m³) of 500, 500, 390, 250, and 140 for 10-min, 30-22 min, 1-hr- 4-hrs, and 8-hrs, respectively were adopted (motion by Bob Benson, second by Jim 23 Holler; Appendix H: 16 yes; 2 no; 3 abstain). It was decided to include a footnote for the AEGL-24 25 3 values noting that lethal air concentrations are unavailable for humans and animals and that

- lethal air concentrations may not be attainable. 26
- 27

	AEGL Values for Malathion											
Classification	10-minute	30-minute	1-hour	4-hour	8-hour	Endpoint (Reference)						
AEGL-1 (Nondisabling)	15 mg/m ³	15 mg/m ³	15 mg/m ³	15 mg/m ³	15 mg/m ³	Sporadic clinical signs in rats (US EPA 2000)						
AEGL-2 (Disabling)	150 mg/m ³	150 mg/m ³	120 mg/m ³	77 mg/m ³	50 mg/m^3	Clinical signs in rats (US EPA 2000)						
AEGL-3* (Lethal)	500 mg/m ³	500 mg/m ³	390 mg/m ³	250 mg/m ³	140 mg/m ³	6900 mg/m ³ (5-hr exposure); highest available exposure for any species						



29 30 concentrations of malathion may not be possible.

- 31
- 32 33

34 35

Staff Scientist: Jennifer Rayner, ORNL

Chemical Manager: Daniel Sudakin, Oregon St. Univ. 36

37

Jennifer Rayner reviewed the extremely limited information on this chemical (Attachment 14). 38

The low vapor pressure of mevinphos likely precludes significant inhalation exposure and route-39

Mevinphos (CAS No. 7786-34-7)

to-route extrapolation may be considered. The possibility of a position paper on route-to-route 1 extrapolation was discussed. The SOP addressed this issue but does not provide specific 2 guidance on procedures/methods. Paul Tobin will work with OPP to come up with a scientific 3 4 approach for the pesticides of AEGL concern. Gail Chapman also mentioned the availability of cholinesterase inhibition data in one of the mevinphos papers and queried how these data might 5 be used in the mevinphos assessment. Deliberation on mevinphos was deferred until "credible" 6 route-to-route extrapolation procedures are investigated. 7 8 9 Bromoacetone (CAS No. 598-31-2) 10 11 Staff Scientist: Cheryl Bast, ORNL 12 Chemical Manager: Roberta Grant, TX Commission Environ. Quality 13 14 Cheryl Bast presented an overview of the data and draft AEGL values (Attachment 15). 15 Proposed AEGL-1 values were based on a concentration causing ocular irritation in 2/6 humans 16 (0.1 ppm) (Dow Chemical, 1968). An intraspecies uncertainty factor of 3 was applied because 17 contact irritation is a portal of entry effect and is not expected to vary widely between 18 19 individuals. An interspecies uncertainty factor of 1 was applied because the study was conducted in humans. Time scaling was not applied in the development of the AEGL-1 values. 20 The critical effect (ocular irritation) is a function of direct contact with the bromoacetone vapor 21 and not likely to increase with duration of exposure (NRC, 2001). However, because of the lack 22 of human data beyond a few seconds, a modifying factor of 3 was applied. Although the 23 concentration-response relationship for bromoacetone is not particularly steep, the AEGL-3 24 values were divided by 3 to derive proposed AEGL-2 values for bromoacetone. This approach 25 26 was utilized because use of the rat irritation data as a point-of-departure yields AEGL-2 values essentially identical to AEGL-3 values calculated from lethality data. 27 28 Proposed AEGL-3 values were based on rat lethality data of varying exposure 29 30 concentrations and durations (Dow Chemical, 1968). Experimental concentrations ranged from 1 to 131 ppm and durations ranged from 6 to 120 minutes. The threshold for lethality at each 31 32 AEGL-3 exposure duration was calculated using the probit-analysis based dose-response program of ten Berge (2006). The threshold for lethality was set at the LC_{01} . The data indicated 33 a time-scaling value of 1.256 ($C^{1.256} x t = k$). These calculated values were used as the basis for 34 the AEGL-3 values. Inter- and intraspecies uncertainty factors of 3 each were applied (total 10) 35 and are considered sufficient because bromoacetone is an irritant (lacrimation, nasal discharge, 36 37 gasping, wheezing, and labored breathing in rats and ocular irritation in humans; Dow Chemical, 38 1968) and clinical signs are likely caused by a direct chemical effect on the tissues. This type of 39 portal-of-entry effect is not likely to vary greatly between species or among individuals. 40 Calvin Willhite suggested mentioning chloroacetone in the structure-activity section of the TSD. 41 A motion was made by Calvin Willhite (second by Gail Chapman) to adopt the AEGL values as 42 presented. The motion passed (Appendix I: 19 yes; 0 no; 0 abstain). 43 44

	AEGL Values for Bromoacetone (ppm)											
Classification	10-minute	30-minute	1-hour	4-hour	8-hour	Endpoint (Reference)						
AEGL-1 (Nondisabling)	0.011 ppm	0.011 ppm	0.011 ppm	0.011 ppm	0.011 ppm	Ocular irritation in humans (Dow Chemical, 1968)						
AEGL-2 (Disabling)	1.4 ppm	0.57 ppm	0.33 ppm	0.11 ppm	0.063 ppm	One-third the AEGL-3 Values						
AEGL-3 (Lethal)	4.1 ppm	1.7 ppm	0.98 ppm	0.32 ppm	0.19 ppm	Threshold for lethality (LC_{01}) in rats (Dow Chemical, 1968)						

Phosphorus Pentachloride (CAS No. 10026-13-8)

Staff Scientist: Carol Wood, ORNL Chemical Manager: Bob Benson, U.S. EPA

7

8 Bob Benson, chemical manager, made brief introductory remarks. Carol Wood, author of the 9 TSD, then presented a discussion of the inhalation data available for the chemical (Attachment 10 16). The human data consisted of a case report of an industrial accident, a laboratory animal 11 study available only in a secondary report, and another laboratory animal study with only limited 12 experimental details presented (Molodkina, 1973). After a brief discussion of the feasibility of 13 using data on PCl₃ or POCl₃ to derive values for PCl₅, Bob Benson moved that the chemical be 14 place in holding status and request that ORNL try to obtain additional information from the 15 producer of the chemical. Dieter Heinz seconded the motion. The motion was approved 16 unanimously by non-ballot vote (Appendix J). 17 18 19 20 Nitrogen Trifluoride (CAS No. 7783-54-2) 21 22 23 Staff Scientist: Sylvia Talmage, ORNL Chemical Manager: Bob Benson, U.S. EPA 24 25 Bob Benson, chemical manager, made brief introductory remarks. Sylvia Talmage, author of the 26 TSD, then presented a discussion of the inhalation data available for the chemical (Attachment 27 17). There are no human data available. However, there is a fairly robust data set in laboratory 28 animals with lethality studies in four species with less than a two-fold difference in response. 29 There are also repeat-exposure and subchronic studies in rats, developmental/reproductive 30 studies in rats, and genotoxicity studies. For AEGL derivation the primary effect is the 31 formation of methemoglobin. Data from the dog, the most appropriate species, was used to 32 derive all AEGL values. For all values an interspecies UF of 1 and an intraspecies UF of 10 33 were used. Time scaling was done with the experimentally derived n = 1 from the lethality 34 studies using the ten Berge (2006) regression analysis program. Draft AEGL-1 values for the 35 formation of 15% methemoglobin were 1200 ppm, 400 ppm, 200 ppm, 50 ppm, and 25 ppm for 36 10 minutes to 8 hours, respectively. Draft AEGL-3 values for the formation of 70% 37 methemoglobin were 5000 ppm, 1700 ppm, 860 ppm, 220 ppm, and 110 ppm for 10 minutes to 8 38 hours, respectively. Draft AEGL-2 values were derived by averaging AEGL-1 and AEGL-3 39

values and correspond to the formation of 42% methemoglobin with values of 3100 ppm, 1100

2 ppm, 530 ppm, 140 ppm, and 68 ppm for 10 minutes to 8 hours, respectively. Aniline

3 methemoglobin information was used as a reference for nitrogen trifluoride. Bob Benson moved

that these values be accepted. Mark Baril seconded the motion. The motion passed (Appendix
K: 19 yes; 0 no; 1 abstain).

5 6

		AEGL V	alues for Nitro	gen Trifluoride	e (ppm)	
Classification	10-minute	30-minute	1-hour	4-hour	8-hour	Endpoint (Reference)
AEGL-1 (Nondisabling)	1200 ppm	400 ppm	200 ppm	50 ppm	25 ppm	≤15% methemoglobin formation in monkeys and dogs following 60-minute exposure to 2000 ppm (Vernot et al. 1973)
AEGL-2 (Disabling)	3100 ppm	1100 ppm	530 ppm	140 ppm	68* ppm	Estimated 43% methemoglobin in dogs: midpoint of AEGL-1 and AEGL-3 (Vernot et al. 1973)
AEGL-3 (Lethal)	5000 ppm	1700 ppm	860 ppm	220 ppm	110 ppm	Regression analysis of dog lethality data of Vernot et al. (1973) calculated with the ten Berge (2006) program

7

*Due to a typographical error in presentation material, the balloted value was 55 ppm.

ADMINISTRATIVE MATTERS

Future Meetings:

April 14-16, 2009 in Alexandria, VA. September 9-11, 2009 (Paris, Montreal or Denver) December 2-4, 2009 (perhaps Orlando, Florida)

All items in the agenda were discussed as thoroughly as the time permitted. The meeting highlights were prepared by Cheryl Bast, Sylvia Talmage, and Robert Young, Oak Ridge National Laboratory, and Bob Benson and Iris Camacho, U.S. EPA.

LIST OF ATTACHMENTS

The attachments were distributed during the meeting and will be filed in the EPA Docket Office.

- Attachment 1. Meeting 47 agenda
- Attachment 2. Meeting 47 attendee list
- Attachment 3. Chlorosilanes presentation
- Attachment 4. Acrylonitrile response to FR comments presentation
- Attachment 5. OP issues-Virginia Moser presentation
- Attachment 6. Allyl alcohol- LyondelleBasell/Fowles
- Attachment 7. Allyl alcohol presentation- Troxel/Benson
- Attachment 8. Tear gas presentation
- Attachment 9. Ricin presentation
- Attachment 10. Dichlorvos presentation
- Attachment 11. Dicrotophos presentation
- Attachment 12. Fenamiphos presentation
- Attachment 13. Malathion presentation
- Attachment 14. Mevinphos presentation
- Attachment 15. Bromoacetone presentation
- Attachment 16. Phosphorus pentachloride presentation
- Attachment 17. Nitrogen trifluoride presentation
- Attachment 18. NAC- 47 meeting certification

LIST OF APPENDICES

- Appendix A. Ballot for approval of NAC-46 meeting highlights
- Appendix B. Final NAC-46 Meeting Highlights
- Appendix C. Ballot for chlorosilanes
- Appendix D. Ballot for allyl alcohol
- Appendix E. Ballot for tear gas
- Appendix F. Ballot for ricin
- Appendix G. Ballot for dichlorvos
- Appendix H. Ballot for malathion
- Appendix I. Ballot for bromoacetone
- Appendix J. Ballot for phosphorus pentachloride
- Appendix K. Ballot for nitrogen trifluoride

AEGL-47-FINAL

Chemical: FL ME ME Action: Propo	ПСЕТТ 1026 AC 7H72 7H72 7H0X	NAC MORE ETATE FLUOR YETHTL	CAEC HINE SAL MERCU Inter	TS	CAS Reg. N CAS Reg. N Act. Are Other	11 14 10 14 10 10 10 10 10 10 10 10 10 10 10 10 10 1	6 2009 MIFLUN MARVE ENCYCL IUM TIZAET	DOACE T FLUDA FLUDA FLUDA FLUDA FLUDA	OAC COFH	ETATE CSTHATE ISULFOTETERM
Chemical Man						77 Scientist		19 172		
NAC Member		AEGL2	AEGL3	LOA	NAC Member	AEGL		AEGL3	Ľ	Appendix C
Henry Anderson			· 	<u> </u>	John Hinz	~			+	
Marc Baril	~		+		Jim Holler				-+	
Lynn Beasley	<i>i</i> ⁄				Glenn Leach					
Alan Becker	~				Richard Niemeier					
Robert Benson	5			-	Susan Ripple				-	
Edward Bernas					George Rusch, Chair					
Iris Camacho	1		-		Daniel Sudakin				_	
Gail Chapman				1	Marcel vanRaaij					
George Cushmac					Calvin Willhite	~				
David Freshwater					George Woodall	/				
Ralph Gingell					Alan Woolf					
Roberta Grant	1									
Dieter Heinz	~									
					TALLY					

PASS/ FAIL

PPM, (mg/m ³)	10 M	lin	30 Mi	n	1 Hr		4 Hr		8 Hr	
AEGL 1	• • • • • • • • • • • • • • • • • • •	.)	, ()	, (· ·· ·· ··)		_)_
AEGL 2	,()	,()	,()	,()	,()
AEGL 3	,()	,()	, ()	,()	,()
LOA						L		I		
* = >10% LEL										
** = ≥ 50% LEL										
*** = >100% LEL										

NR= Not Rec	commended	due to			
AEGL 1 M AEGL 2 M AEGL 3 M	lotion by:	Ryple		Second by: Second by: Second by:	Hang
	lotion by:			Second by:	
Approved by			_ DFO:	Panterti	Date: <u>4/14/09</u>

NAC/AEGL-Meeting 48: April 14-16, 2009	0	ĩаc	AEGL	Meetin	<u>1</u> 48: . !	April 1	14-16 ,	3908
--	---	-----	------	--------	------------------	---------	----------------	------

Chemical: Maisen PENTOXIPE AMBENIC TRICHLORIPE Ŕ

CAS Reg. No.:

Other

Appendix D

Action: Proposed _____ Interim____

Chemical Mar NAC Member	AEGLI	AEGL2	AEGL3	LOA	NAC Member	AEGL1	AEGL 2	AEGL3	LOA
		Ĺ							
Henry Anderson					John Hinz				
Marc Baril					Jim Holler				
Lynn Beasley					Glenn Leach				-
Alan Becker					Richard Niemeier				
Robert Benson			+		Susan Ripple		-	<u> </u>	
Edward Bernas					George Rusch, Chair				
Iris Camacho					Daniel Sudakin				
Gail Chapman					Marcel vanRaaij		-		
George Cushmac				-	Calvin Willhite		-	•	
David Freshwater					George Woodall				
Ralph Gingell					Alan Woolf		-		
Roberta Grant									
Dieter Heinz							· .		
					TALLY	r			
				+	PASS/ FAIL		-		

PPM, (mg/m ³)	10 Min			n	1 Hr		4 Hr		8 Hr	
AEGL 1	• •,•(• • • • •).	, ()	• ••••• •••(••••		, (,(
AEGL 2	,()	,()	,()	,()	, ()
AEGL 3	,()	,()	,()	, ()	,()
LOA				I						
* = ≥10% LEL	-									
** = ≥ 50% LEL										
*** = ≥100% LEL										

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account. #* Intsufficient DATA - flace on Holding Natled List.

NR= Not Recommended due to____

AEGL 1	Motion by: _	Grant		Second by: _	Mint	e
AEGL 2	Motion by:_			Second by:		
AEGL 3	Motion by: _			Second by:		
LOA	Motion by:			Second by:		
Approved	l by Chair:		_ DFO: _	landsolo	Date: _	4/14/09

·		NAC	C/AEC	il. Me	6110 (48: Apr	·il 14-1	6, 2009				
Chemical:	ICI	Н			CAS Reg. N					ppendix I	
Action: Propo	sed		Inter	im	Other /						
Chemical Man	ager:	JHO	LLER		Staff	Scientist	: B, Y	00000	5	20 <u>2</u> 12	• 7
NAC Member	AEGLI	AEGL2	AEGL3	LOA	NAC Member	AEGLI	AEGL 2	AEGL3	LOA		
Henry Anderson					John Hinz						
Marc Baril					Jim Holler						
Lynn Beasley			<u> </u>		Glenn Leach						
Alan Becker		+			Richard Niemeier						
Robert Benson					Susan Ripple						
Edward Bernas					George Rusch, Chair						
Iris Camacho					Daniel Sudakin						
Gail Chapman					Marcel vanRaaij						
George Cushmac					Calvin Willhite						
David Freshwater					George Woodall	-					
Ralph Gingell			-		Alan Woolf						
Roberta Grant											
Dieter Heinz											
					TALLY	r					
					PASS/ FAIL						
PPM, (mg/m ³)		10 Min	3	80 Min	1 Hr	4	4 Hr.	1	8 Hr]	
AEGL 1				• ())	(().	-	

AEGL 2	,()	,()	, ()	, ()	,()
AEGL 3	,()	, ()	,()	,()	,()
LOA										
* = ≥10% LEL										
** = ≥ 50% LEL										
*** = ≥100% LEL										

*Safety considerations against the hazard(s) of explosion(s) must be taken into account. ** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account. # Motion to Record SIDER RICIN AEGL VALUES, BASET ON NEW PATA, (UNANIMOUS) NR= Not Recommended due to______

AEGL 1	Motion by:	172	Second by: _	WOODALL
AEGL 2	Motion by:		Second by:	
AEGL 3	Motion by:		Second by:	
LOA	Motion by:		Second by:	
Approved	by Chair:		Paulsth	Date: 4/15/09

NAC/AEGL Meeting 48: April 14-16, 200	1	A174	EGL	Maat	ing 48:	April	14-)	10,	2009
---------------------------------------	---	------	-----	------	---------	-------	------	-----	------

UAS Reg. No.: 14-5 - 33-9 Other

Appendix F

Chemical: Action: Proposed /

Salerin

Chemical Man	ager:	14, 5		Staff	Scientist:	<u> </u>	BAST	
NAC Member	AEGLI	AEGL2	A264.	C Member	AEGLI	AEGL 2	AEGL3	LOA
Henry Anderson	7	7	Y		Y	У	4	-
Marc Baril	7	7	7	Jim Holler	γ	Y	\checkmark	
Lynn Beasley	7	۲	Y .	Glenn Leach	γ	7	Y	
Alan Becker	7	Y	4	Richard Niemeier	Y	Y	7	
Robert Benson	Y	Y	Y	Susan Ripple	Y	У	Y	
Edward Bernas	7	4	4	George Rusch, Chair	Y	\checkmark	Y	
Iris Camacho	Y	Y	Y	Daniel Sudakin	Y	Y	Y	
Gail Chapman	7	У	У	Marcel vanRaaij	У	Y	У	
George Cushmac	7	Y	Y	Calvin Willhite	Y	Y	У	
David Freshwater	۲	Y	Y	George Woodall	У	Y	Y	
Ralph Gingell	Y	7	4	Alan Woolf	У	У	Y	
Roberta Grant	Y	Y	Y					
Dieter Heinz	Y	Y	7					
				TALLY	24/24	24/24	24/24	_
				PASS/ FAIL	P	P	P	

$PPM, (mg/m^3)$	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL 1	.(50)		,(4,0)	,(2,6)	,(2,0)
AEGL 2	,(34)	,(20)	,(14)	,(7,0)	,(5,0)
AEGL 3	,(54)	,(42)	,(30)	,(17)	,(/3)
LOA					
* = ≥10% LEL					
** = ≥ 50% LEL					
*** = ≥100% LEL					

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recommended due to_

AEGL 1	Motion by: Numer	Second by:	Heim
	Motion by:	Second by:	~ >
AEGL 3	Motion by:	Second by:	
LOA	Motion by:	Second by:	
Approved	by Chair:DFO: _D	Panes The	Date: <u>4/14/09</u>

- NAC/YEGU Meer	n 48: April 14-16, 2009
-----------------	-------------------------

Chemical: POTASSIUM CYANDE CASKER No.: 151 - 50 - 80-200

Action: Proposed / Interim

Appendix G

٠, ۲,

Chemical Mar NAC Member	AEGLI	AFCI 2	AEGL3	LOA	NAC Wenuer	AEGLI		AEGL3	LOA
NAC Member	ALGLI	ALGL2	ALGES	LUA		ALGLI	ALGE 2	AEGLJ	
Henry Anderson	У	7	Y		John Hinz	Ŷ	7	Y	
Marc Baril	У	Y	Y		Jim Holler	7	7	7	
Lynn Beasley	4	У	7		Glenn Leach	Y	У	У	
Alan Becker	У	γ	У		Richard Niemeier	У	У	\mathbf{v}	
Robert Benson	У	Y	Y		Susan Ripple	У	7	7	
Edward Bernas	У	γ	Y		George Rusch, Chair	У	У	У	
Iris Camacho	Υ.	У	Y		Daniel Sudakin	Y	Y	Y	
Gail Chapman	У	У	У		Marcel vanRaaij	7	Y	7	
George Cushmac	У	У		-	Calvin Willhite	7	У	У	
David Freshwater	4	γ	. Y		George Woodall	У	Y	7	
Ralph Gingell	4	γ	У		Alan Woolf	Y	Y	Y	
Roberta Grant	Y	Y	Y						
Dieter Heinz	7	γ	4						
					TALLY	*			
					PASS/ FAIL				

PPM , (mg/m ³)	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL 1		,(6,6)	,(5,3)		······································
AEGL 2	,(45)	,(27)	,(19)	,(9,3)	,(6,6)
AEGL 3	,(72)	,(56)	, (40)	,(73)	,(18)
LOA					
* = ≥10% LEL					
** = ≥ 50% LEL					
*** = ≥100% LEL				_	

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recommended due to_____

AEGL 1	Motion by: Remeier	Second by:	Him	
	Motion by:	Second by:		
AEGL 3	Motion by:	Second by:	de la	
LOA	Motion by:	Second by:		
Approved	by Chair: DFO:	Intoth	Date: _	4/14/09

NACIAEGL Meeting 48: April 14-16, 200	90	en se	16,	•	1	I	nü	Λp	48:	eeting	M	GL	AE]/	1	N
---------------------------------------	----	-------	-----	---	---	---	----	----	-----	--------	---	----	----	----	---	---

Chamical: proson cushibe

CAS Reg. No.: 57700 - 3

isetion: Proposed Ye

. ÷ 1

1

14 64

Interim____Other____

Appendix H

Chemical Man	lager:	R.C	SINGE	L	Staff S	Scientist	С.	18 4 M	-
NAC Memoer	AEGLI	AEGL2	AEGL3	LOA	NAC Member	AEGL!	AEGU2	A.: 134.)	LOA
Henry Anderson	У	×	Y		John Hinz	Y	Y	4	-}
Marc Baril	у	У	У		Jim Holler	Y	Y	У	
Lynn Beasley	Y	У	Y		Glenn Leach	У	У	У	
Alan Becker	У	У	Y		Richard Niemeier	У	У	У	
Robert Benson	У	Y	У		Susan Ripple	У	Y	Y	
Edward Bernas	γ	У	Y		George Rusch, Chair	7	У	У	
Iris Camacho	Y	Y	Ý		Daniel Sudakin	У	¥	Y	
Gail Chapman	У	γ	Y		Marcel vanRaaij	P	1	p	
George.Cushmac	Y	У	Y		Calvin Willhite	γ	Y	Y	
David Freshwater	У	У	Y		George Woodall	У	Y	Y	<u> </u>
Ralph Gingell	У	У	Y		Alan Woolf				
Roberta Grant	Y	Y	Y						<u> </u>
Dieter Heinz	У	Ý	Ý						
					TALLY		-		
					PASS/ FAIL				1
					PASS/ FAIL		,		

PPM, (mg/m))	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL 1	-,(4,7-)		,(3,8)	- ,(2,4)	
AEGL 2	,(32)	,(19)	,(]3)	,(6,6)	,(4.7)
AEGL 3	, اک)	,(39)	,(28)	,(16)	,(12)
LOA				I	
* = ≥10% LEL					
** = ≥ 50% LEL					
*** = ≥100% LEL					

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recommended due to

AEGL 1	Motion by: Numer	Second by:	Him
AEGL 2	Motion by:	Second by:	
AEGL 3	Motion by:	Second by:	
LOA	Motion by:	Second by:	
Approved	d by Chair:	. MSTA	Date: <u>4/14/09</u>

Chemical Mar	nager:	JI	4 HO	LLE	ک	Staff S	Scientist	: BOB	Yourd	3
NAC Member	AEGLI	AEGL2	AEGL3	LOA	NA	C Member	AEGLI	AEGL 2	AEGL3	LOA
Henry Anderson	Ý	Y	У		Joh	n Hinz	P	P	У	
Marc Baril	Y	\checkmark	P		Jim	Holler	У	7	Y	
Lynn Beasley	Ý	\neg	Y			nn Leach	Ý	7	Y	
Alan Becker	Y	Y	P		Ric	hard Niemeier	У	Y	Y	
Robert Benson	P	P	Y		Sus	an Ripple	У	7	Y	
Edward Bernas	У	\prec	P		Geo Cha	orge Rusch, air	У	\forall	Y	
Iris Camacho	Y	У	Ч		Dar	niel Sudakin	У	\forall	Y	
Gail Chapman	Y	\forall	P		Ma	rcel vanRaaij	P	P	7	,
George Cushmac	Ý	Y	7		Cal	vin Willhite	Y	Y	Y	
David Freshwater	7	Y	7		Geo	orge Woodall	Y	Y	Y	
Ralph Gingell	7	Y	Y		Ala	n Woolf	У	γ	Ы	
Roberta Grant	P	P	Y							
Dieter Heinz	Y	4	Y				1			
						TALLY	200	Pbo	18/20	
						PASS/ FAIL	f	P	P	
PPM, mg/m ³		10 Min		30 Min	_ [1 Hr		4 Hr	8	Hr
AEGL 1		,(0,17)	,(0,05	6)	,(0,028)		, (), 0069)		2,0035
AEGL 2		,(0,50)	,(0,17)	7)	,(0,083)		,(0,021)	,(0,010
AEGL 3		,(36)	,(25)	,(13)		<u>,(3'/)</u>		1.6)
LOA										_
* = ≥10% LEL	_				_					

CAS Reg. No.: 1794 - 86 -1 Chemical: (HOSGENE ON ME

NAC/ Meeting 48: April 14-16, 2009

Appendix I

Action: Proposed_______Other____Other_____Other____Other_____Other____Other_____Other_____Other_____Other_____Other____Other____Other____Other____Other____Other_____Other_____Other_____Other_____Other_____Other_____Other_____Other_____Other____Other_____Other____Other____Other____Other____Other____Other____Other___Other___Other____Other____Other____Other____Other___Other___Other___Other___Other____Other____Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other__Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other___Other____Other____Other____Other___Other___Other___Other___Other____Other___Other__Other___Other___Other___Other__Other__Other___Other___Other__Other__Other___Other___Other__Other__Other___Other___Other__Other__Other__Other__Other__Other__Other__Other__Other__Other__Other_Other_Other_Other_Other_Other_Other_Other_Other_Ot

** = ≥ 50% LEL

*** = ≥100% LEL

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

.

NR=Not	Recommended due to		
	Motion by: With to	Second by:	Bail
AEGL 3	Motion by: Willing	Second by:	Hamo-
LOA	Motion by:	Second by:	8/
Approved	by Chair:MDFO:	Cartsto	Date: 4/14/09

NAC/AEGL	Meeting	48 :	April]4	16.	2009
----------	---------	-------------	-------	----	-----	------

Chemical: ERFLUOROISOBUTYLEME CAS Reg. No.: 38 - 11-8

Appendix J

•

Chemical Man	lager:	0, 10	SCH			scientist:		BA87	
NAC Member	AEGL1	AEGL2	AEGL3	LOA	NAC Member	AEGLI	AEGL 2	AEGL3	LOA
Henry Anderson	Y	Y	Y		John Hinz	Y	7	У	
Marc Baril	У	Y	Y		Jim Holler	Y	Y		
Lynn Beasley	X	Y	\checkmark		Glenn Leach	A	A	A	
Alan Becker	Y	Y	\forall		Richard Niemeier	Y	$\overline{\gamma}$	\succ	
Robert Benson	Y	\checkmark	\forall		Susan Ripple	Ý	\prec	\mathbf{Y}	
Edward Bernas	Y	Y	Ч		George Rusch, Chair	Y	\vee	Y	
Iris Camacho	Y	Y	У		Daniel Sudakin	Y	\checkmark	\checkmark	
Gail Chapman	Y	Y	Y		Marcel vanRaaij	Y	Y	¥	
George Cushmac	У	\checkmark	Y		Calvin Willhite	У	Y	\forall	
David Freshwater	Y	\prec	Y		George Woodall	У	\forall	Y	
Ralph Gingell	7	Y	Y		Alan Woolf	У	X	Y	
Roberta Grant	Y	Y	\forall						
Dieter Heinz	X	4-	/						
					TALLY				
					PASS/ FAIL				

$PPM, (mg/m^3)$	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL 1	,(NR)	- , (- MR)	,(NR-)-	- (Mr)	- , (M2 -)
AEGL 2	, (0,67)	,(0,22)	,(0,11)	, (1,128)	, (0,014)
AEGL 3	,(2,0)	,(0,67)	, (0, 33)	, (0,083)	,(0,042)
LOA					
* = ≥10% LEL					
** = ≥ 50% LEL					
*** = ≥100% LEL					

*Safety considerations against the hazard(s) of explosion(s) must be taken into account. ** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not	Recommended due to lach 1 de	ata		
	Motion by: <u>Memire</u> Motion by: <u>Motion by:</u>	Second by: Second by: Second by:	Heim	
LOA	Motion by:	Second by:		
Approved	by Chair: 6207 M. C. BFO:	fantstin	Date:	4/14/09

	1			• • •	CAS Reg. N	o.: 23	135	82-	0	
Action: Propos	5+* 1		Inter	m	Other					Appendix K
Chemical Man	ser:	. M	m		Staff	Scientist	Vala	nella se		
	AEGLI	、 ·	AEGL3	LOA	NAC Member	AEGLI	AEGL 2	AEGL3	LOA	
Henry Anderson	Y	X	Y		John Hinz	X	Y	У		
Marc Baril	Y	Y	Y		Jim Holler	Y	Y	Y		
Lynn Beasley	Y	Ý	X		Glenn Leach	Y	Y	Y		
Alan Becker	4	У	Y		Richard Niemeier	У	\checkmark	Y		
Robert Benson	\prec	\checkmark	Y	\backslash	Susan Ripple	A	A	A		
Edward Bernas	1	Y	У		George Rusch, Chair	γ	γ	У		
Iris Camacho	7	Ý	\forall		Daniel Sudakin	Ý	Y	¥		
Gail Chapman	X	Y	\checkmark		Marcel vanRaaij	N	гł	M		
George Cushmac	Ŷ	Y	Υ		Calvin Willhite	P	P	P		
David Freshwater	7	7	Y		George Woodall	Y	Y	Y		
Ralph Gingell	7	Y	У		Alan Woolf	A	A	A		
Roberta Grant	Y	Y	Y							
Dieter Heinz	X	Y	4			nd				
					TALLY	10-1	29/21	20/21		
					PASS/ FAIL	Λ	ρ	P		
PPM, (mg/m ³)		10 Min	3	0 Min	1 Hr	4	Hr	8	Hr]
AEGL 1	9.	(47)),	0,60) - , (0,39 -)) \-,	(0,16)	,	O1+})	
AEGL 2	,	(1.9)),	(0,90), (0,57)		(0,24)	,(0,16)	
AEGL 3	,	(5,3)),	(2.7),(1,2)	,	(8,73)	, (0,48)	
LOA										
* = ≥10% LEL										
** = ≥ 50% LEL										
*** = >100% LE								\sum	_	
*Safety considerations against the hazard(s) of explosion(s) must be taken into account. ** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.										
NR= Not Recon	nmend	led due f	to					_ \	- X	
	on by:		in			l by:	Bette	$\boldsymbol{\mathcal{C}}$	19	ÉZ
	on by:		1		Second					$\langle \rangle$
AEGL 3 Motion by: Second by:										
LOA Motion by: Second by:										
Approved by C	hair: 7	P)	, <u> </u>	_6	FO: Jaul	5Th	_ Date:	4/15	09	

NAC/AEGL	Meeting	48: April	14-16. 2009
	meening	TO: April	11.10, 2007

. .

Chemical: 🔿					CAS Reg. No				
Action: Propo	sedl		tai	าย .	Other A	ljuðn	news t	E UF/	yolnes
Chemical Man	ager:	TOG	19		Staff S	Scientist	TAL	MAGE	
NAC Member	AEGLI	AEGL2	AEGL3	-JOA		AEGL1 ·	AEGL 2	AEGL3	LOA
Henry Anderson	N	N	H		John Hinz	У	γ	У	
Marc Baril	Y	У	У		Jim Holler	\checkmark	Y	7	
Lynn Beasley	Y	7	Y		Glenn Leach	4	Y	7	
Alan Becker	P	P	f		Richard Niemeier	7	У	7	
Robert Benson	4	7	Y		Susan Ripple	A	A	A	
Edward Bernas	P	P	P		George Rusch, Chair	X	γ	4	
Iris Camacho	Y	Y	Y		Daniel Sudakin	γ	γ	γ	
Gail Chapman	×	Y	1		Marcel vanRaaij	Y	7	7	
George Cushmac	Y	Y	4		Calvin Willhite	γ	7	4	
David Freshwater	Y	Y	1		George Woodall	Y	Y	7	
Ralph Gingell	\neg	7	7		Alan Woolf	A	A	A	
Roberta Grant	Y	γ	7						
Dieter Heinz	Á	A	A						
		· · · · ·			TALLY				
				-	PASS/ FAIL				

NAC/AEGL Meeting 48: April 14-16, 2000

Appendix L

PPM, (mg/m ³)	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL 1	.(3,6)	,([,8 -)	,(1,2)		
AEGL 2	,(5,3)	,(2,7)	,(1,8)	,(0,73)	,(0,47)
AEGL 3	,(16)	,(8.2)	,(5,3)	,(2,2)	,(1,4)
LOA					
* = ≥10% LEL					
** = ≥ 50% LEL					
*** = ≥100% LEL					

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s)) of explosion(s) must b	be taken into account.
** and ***Extreme safety considerations against the hazard(s) * Amend previous Vallot (neall e	a lier vote + C	hange UF from 10 to 3
NR= Not Recommended due to		INTRA
AEGL 1 Motion by: Him	Second by:	Beron baril
AEGL 2 Motion by:	Second by:	
AEGL 3 Motion by:	_ Second by:	
LOA Motion by:	Second by: _	
Approved by Chair:DFO:	Cand SV.h	Date: 4/15/09

Action: Propo	sed	/	Inter	illi	Other		A	ppendix	M
Chemical Man	ager	Johi	2		Staff S	Scientist	The	nage	• • • •
NAC Member	AEGL	1 AEGL2	AEGL3			AEGLI	AEGL 2	AEGL3	LOA
Henry Anderson	Y	Y	P	Jo	ohn Hinz	У	Ý	7	
Marc Baril	Ý	P	P	Ji	m Holler	Y	Y	Y	
Lynn Beasley	A	A	A	G	lenn Leach	A	A	A	
Alan Becker	X	P	P	R	ichard Niemeier	7	4	Y	
Robert Benson	Y	Y	Y	S	usan Ripple	7	Y	\checkmark	
Edward Bernas	Y	Y	4		eorge Rusch, hair	Y	Y	Y	
Iris Camacho	Y	P	H		aniel Sudakin	Y	Y	Y	
Gail Chapman	A	A	A	M	larcel vanRaaij	P	Y	Y	
George Cushmac	Y	X	Y	C	alvin Willhite	Y	Ý	· Y	
David Freshwater	Ý	Y	7	G	eorge Woodall	Ý	Y	Y	
Ralph Gingell	Ý	Y	7	A	lan Woolf	A	A	A	
Roberta Grant	Y	P	ot				*		
Dieter Heinz	\checkmark	\checkmark	4						
	/	1	1-1		TALLY	19/19	16/16	15/17	
					PASS/ FAIL	P	P	ρ	
PPM (mg/m ³)		10 Min		30 Min	1 Hr	4	Hr	8	Hr
AEGL 1		,(N/-)	,(<u>NA</u>)	,(AA)	· · · · · · ,	(]), · · · (
AEGL 2		•			5.7 ,()	1)
AEGL 3		,(1 711	(JB)	17,(////////////////////////////////////		(AAX)) 52-,((MAR)
LOA				/ 04 -					
* = ≥10% LEL		. –		<u>.</u>					
** = ≥ 50% LEL									

NAC/AEG1. Meeting 48: April 14-16, 2009

CAS Reg. No.: 16752-97=5

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recommended due to

*** = ≥100% LEL

Chemical: METHOMYL

AEGL 1	Motion by:	HINZ	Second by:	HEINZ	
AEGL 2	Motion by:_	HEIN2	Second by:	HIMZ	
AEGL 3	Motion by:	HIN2	Second by: _	HEIN2	
LOA	Motion by:		Second by:		
Approved	by Chair: 🗡	MM DFO:	Jants Mi	Date: <u>4</u>	115/09

тоты									F
Chemical: A	DIC	ARB			CAS Reg. No	o.: 116	5-06-3	3	
Action: Propos	sed	\checkmark	Inter	rim	Other	· ·			
Chemical Man	ager:	Tol	i. Am		Staff S	scientist	· VM	muge	
NAC Member		I AEGL2	AEGL3	LOA		AEGLI	AEGL 2	AEGLI	LÓA
Henry Anderson	P	1	l	-	lohn Hinz	R	P	1	
Marc Baril	Y	Y	Y		lim Holler	Y	Y	¥	
Lynn Beasley	Y	V	Ý		Glenn Leach	Y	×	Y Y	
Alan Becker	0	1	P		Richard Niemeier	Y	Y	Ý	
Robert Benson	Y	Y	Y	-	Susan Ripple	Â	A	Ā	
Edward Bernas	Y	Ý	Y		George Rusch, Chair	7	V	<u>у</u>	
Iris Camacho	Y	Y	Ý		Daniel Sudakin	Ý	Ý	4	+
Gail Chapman	Y	Ý	Y		Marcel vanRaaij	Y	Ý	Ý	
George Cushmac	Y	ŤΎ	Y		Calvin Willhite	Y	Y	7	
David Freshwater	У	· V	Y		George Woodall	Y	Y	×	1
Ralph Gingell	Y	4	Y		Alan Woolf	ft	A	Â	
Roberta Grant	Y	Y	V						
Dieter Hein2	PJ	A	A						
					TALLY	18/18	18/18	18/18	
					PASS/ FAIL				
PPM, (mg/m ³)	T	10 Min		30 Min	l Hr	4	Hr	8	Ĥr
AEGL 1		,(MR).	.(Mr) ·(nr)	1	(12)	, (AR)
AEGL 2		,(0,16)	,0,11			(0,053)		0,027)
AEGL 3		.(0,47)	.6.32), (0,26)		9.16)		0,081)
LOA			,	<u>.</u>					
* ≈ ≥10% LEL									
** = > 50% LEL	-			e h		P			
*** = ≥100% Lf	EL				···			-	

*Safety considerations against the hazard(s) of explosion(s) must be taken into account. ** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recommended due to_

20.

AEGL	1 Motion by:	Van Rain		Second by:	Wooden	all	,
AEGL	2 Motion by:			Second by:		44	
AEGL	3 Motion by:			Second by: _			_
LOA	Motion by			Second by:			-
6.03×03	SOSSE47450	C. 11/1	Lon	Par. 18. 1.	⊎d3 ¯	57:42	- 6002-21-999

Appendix N

NAC/AMEL 14. ung 18: April 14-16, 2009

Chemical: *fErchlorite Fluor det UAS* No.: 2616-94-6 Action: Proposed / Inter Mater 4

Appendix O

Action: Proposed

Chemical Man	ager:	6. Li	EACH			Scientist:	PAN	9 GL AEGL3	ASS
NAC Member	AEGLI	AEGL2	AEGL3	1.0A	NAC Member	AEGLI	AEGL 2	AEGL3	LOA
Henry Anderson	Y	Y	4		John Hinz	.7	4	\checkmark	
Marc Baril	P	P	P		Jim Holler	Y	Y	¥	
Lynn Beasley	\checkmark	Y	4		Glenn Leach	γ	Ý	\checkmark	
Alan Becker	7	Y	Y		Richard Niemeier	Y	4	Ý	
Robert Benson	7	4	4		Susan Ripple	A	A	A	
Edward Bernas	Y	Y	7		George Rusch, Chair	7	¥	Y	
Iris Camacho	7	7	\checkmark		Daniel Sudakin	Y	Y	$ \gamma $	
Gail Chapman	4	7	Y		Marcel vanRaaij	Y	Y	Y	
George Cushmac	4	Y	\checkmark		Calvin Willhite	Y	Y	Ý	
David Freshwater	7	Ч	4		George Woodall	Y	Y	Y	
Ralph Gingell	A	A	A		Alan Woolf	A	A	A	
Roberta Grant	7	4	4				•		
Dieter Heinz	A	A	P						
					TALLY	19/19	[9] /a	19/19	
					PASS/ FAIL	P	l	9	
						-		_	

PPM, (mg/m ³)	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL 1	,(),{)	<u>, (1,8)</u>	,(_1,5_)	α <u>α</u> (α <i>θ</i> ₁ α9 ₂)	,(0,60)
AEGL 2	,(5,0)	,(5,0)	,(4,0)	,(2.5)	,(1.7)
AEGL 3	,(15)	,(15)	,(17)	,(7.5)	,(3.7)
LOA					
* = ≥10% LEL					
** = ≥ 50% LEL					
*** = ≥100% LEL					

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recommended due to	
AEGL 1 Motion by: Benon	Second by: 7/mg
AEGL 2 Motion by:	Second by:
AEGL 3 Motion by:	Second by:
LOA Motion by:	Second by:
Approved by Chair:	Intes The Date: 4/16/19

NAC/AEGI	. Meeting	48: A)	nril]]	<u>] (</u>).	<u>2909</u>
----------	-----------	---------------	------	-----	---------------	-------------

Chemical: TELLURIUM HEXAFLUORIDE CAS Reg. No .: 9983-80-4

Other____

Appendix P

Action: Proposed

NAJNER

Chemical Ma	nager:	<i>U</i> ·	ANT		Staff Scientist: NATHER				
NAC Member	AEGL1	AEGL2	AEGL3	LOA	NAC Member	AEGL1	AÉGL 2	AEGL3	LOA
Henry Anderson			Y		John Hinz	-		ΓY	
Marc Baril			Ý		Jim Holler		_	Y	
Lynn Beasley			7		Glenn Leach			Y	
Alan Becker			Y		Richard Niemeier			Y	
Robert Benson			γ		Susan Ripple			A	
Edward Bernas			Y		George Rusch, Chair			Y	
Iris Camacho			У		Daniel Sudakin			Y	
Gail Chapman			Y		Marcel vanRaaij			Y	
George Cushmac			Y		Calvin Willhite			Н	
David Freshwater			Y	-	George Woodall			N	
Ralph Gingell			Y		Alan Woolf			A	
Roberta Grant			Y				-		
Dieter Heinz			-A						
			·		TALLY	/			
	-		-		PASS/ FAIL	-		-	

(PPM (mg/m ³)	10 Min	30 Min	1 Hr	4 Hr	8 Hr
AEGL I	,(MR)	· (MR)	,(-MR)		,(M2)
AEGL 2	, (6,032)	, (1,022)	, (0,018)	·(0,011)	, (0,005)
AEGL 3	, (5,096)	, (0,687)	,8,053)	,(0,033)	·(0,017)
LOA					
* = ≥10% LEL					
** = $\geq 50\%$ LEL					
*** = ≥100% LEL					

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and ***Extreme safety considerations against the hazard(s) of explosion(s) must be taken into account.

NR= Not Recor	nmended due to	of data	
AEGL 1 Mot AEGL 2 Mot	·	Second by: Second by:	Him
AEGL 3 Mot	ion by: Benoon	Second by:	Him
	ion by:	Second by:	D 44/10/09
Approved by C	hair:	DFO: <u>{MG//h</u>	Date: <u>4/16 / 09</u>

NAC/AEGL Meeting 48: April 14-16	5,2009	
----------------------------------	--------	--

Interim____

Appendix Q

Chemical: PHOSOGNE

Action: Proposed_____

CAS Reg. No.:

Chemical Mar	Chemical Manager: Staff Scientist:								
NAC Member		AEGL2	AEGL3	LOA	NAC Member	AEGLI	AEGL 2	AEGL3	LOA
Henry Anderson					John Hinz				
Marc Baril					Jim Holler	-			
Lynn Beasley					Glenn Leach				
Alan Becker			-		Richard Niemeier			-	
Robert Benson				1	Susan Ripple			_	
Edward Bernas					George Rusch, Chair				
Iris Camacho					Daniel Sudakin				
Gail Chapman					Marcel vanRaaij				
George Cushmac					Calvin Willhite				
David Freshwater					George Woodall				
Ralph Gingell					Alan Woolf				
Roberta Grant								-	
Dieter Heinz									
					TALLY	r			
					PASS/ FAIL				

$PPM, (mg/m^3)$	10 N	1in	30 Mi	n	1 Hr		4 Hr		8 Hr	
AEGL 1	,(.)	, ().	, (·)	, ()-		.)
AEGL 2	,()	,()	,()	,()	,()
AEGL 3	,()	,()	,()	,()	,()
LOA						1				
* = ≥10% LEL										
** = ≥ 50% LEL							•			
*** = ≥100% LEL										

*Safety considerations against the hazard(s) of explosion(s) must be taken into account.

** and *** I A Dral	Extreme safety considerations against the Ballot to re-came	he hazard(s) of explosion(s) must be taken into according to the photogene values, ba	selon new data.
	Recommended due to		(UNANIMOUS)
AEGL 1	Motion by:	Second by:	
AEGL 2	Motion by:	Second by:	
AEGL 3	Motion by:	Second by:	
LOA	Motion by:	Second by:	

DFO: _

fauls

Date: 4/15/09

			Ň	11	1
Approved	by	Chair:	61	<u></u>	Ľ